Key result
While PT and aPTT tests lacked sensitivity, three anti-Xa assays reliably quantified apixaban concentrations with inter-laboratory precision and accuracy below 11% and 12%, respectively.
Why the study?
Are anti-Xa assays more suitable than standard PT and aPTT tests for quantifying apixaban plasma concentrations?
Are anti-Xa assays more suitable than standard PT and aPTT tests for quantifying apixaban plasma concentrations?
Anti-Xa assays using specific calibrators reliably quantify apixaban concentrations, whereas standard PT and aPTT tests lack sufficient sensitivity for this purpose.
No takes yet. Share an insight, caveat, or question.
Anti-Xa assays may enable targeted apixaban assessment in select emergencies; leaves open standardization and prospective validation before broader use.
Flaujac et al. (2013) studied Apixaban concentration assessment. Anti-Xa assays vs. PT and aPTT tests was evaluated on Inter-laboratory precision and accuracy. While PT and aPTT tests lacked sensitivity, three anti-Xa assays reliably quantified apixaban concentrations with inter-laboratory precision and accuracy below 11% and 12%, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: